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OBJECTIVE — -Cell function in type 1 diabetes clinical trials is commonly measured by
C-peptideresponsetoasecretagogueineitheramixed-mealtolerancetest(MMTT)oraglucagon
stimulation test (GST). The Type 1 Diabetes TrialNet Research Group and the European C-
peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sen-
sitivity, reproducibility, and tolerability of these procedures.
RESEARCH DESIGN AND METHODS — In randomized sequences, 148 TrialNet
subjects completed 549 tests with up to 2 MMTT and 2 GST tests on separate days, and 118
ECPT subjects completed 348 tests (up to 3 each) with either two MMTTs or two GSTs.
RESULTS — Among individuals with up to 4 years’ duration of type 1 diabetes, 85% had
measurable stimulated C-peptide values. The MMTT stimulus produced signiﬁcantly higher
concentrations of C-peptide than the GST. Whereas both tests were highly reproducible, the
MMTT was signiﬁcantly more so (R
2  0.96 for peak C-peptide response). Overall, the majority
of subjects preferred the MMTT, and there were few adverse events. Some older subjects pre-
ferred the shorter duration of the GST. Nausea was reported in the majority of GST studies,
particularly in the young age-group.
CONCLUSIONS — The MMTT is preferred for the assessment of -cell function in thera-
peutic trials in type 1 diabetes.
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T
he measurement of C-peptide in re-
sponse to a stimulus provides a di-
rect measure of -cell function.
Whereas type 1 diabetes results from an
immune-mediated loss of pancreatic
-cells, higher residual -cell function
early in the disease has strong long-term
beneﬁcialeffects(1).Theinternationaldi-
abetes research community has high-
lightedtheneedtoestablishthevalidityof
C-peptide and other assessments used in
clinicaltrialsinrecent-onsettype1diabe-
tes (2), weighing the scientiﬁc properties
of a test against the burden imposed on a
subject.
A recently issued draft guidance
recognized preservation of -cell func-
tion, as measured by C-peptide, as an
appropriate outcome for therapeutic
trialsinearlytype1diabetes(3).Results
from trials using therapies such as im-
munosuppression, T-cell modulation,
B-cellmodulation,costimulationblock-
ade, antigen-speciﬁc therapy, and met-
abolic control are likely to change the
standard of care for individuals with
type 1 diabetes.
Generally, one of two methods for
stimulating C-peptide response is used in
clinicaltrials.Inthemixed-mealtolerance
test(MMTT),commonlyusedintheU.S.,
a liquid meal (Sustacal/Boost) is ingested
in the fasting state with timed measure-
ments of C-peptide over the subsequent
2–4 h. In the glucagon stimulation test
(GST), glucagon is injected intravenously
with timed measurements of C-peptide
over the subsequent 10 min. Two parallel
studies were conducted simultaneously
by the Type 1 Diabetes TrialNet (Trial-
Net) Research Group and the European
C-peptide Trial (ECPT) Study Group to
evaluate the properties and tolerability of
these tests.
RESEARCH DESIGN AND
METHODS— Details about study de-
sign and laboratory and statistical meth-
ods are provided in an online appendix
(available at http://dx.doi.org/10.2337/
dc07-2451).
TrialNet enrolled 148 subjects be-
tween September 2004 and December
2005at14clinicalcentersinNorthAmer-
ica, 1 in Europe, and 1 in Australia. The
ECPT enrolled 118 subjects between
April 2004 and December 2004 in 12 Eu-
ropean centers. Institutional or ethics
board approval was obtained at each site,
and each subject or parent, as appropri-
ate,providedinformedconsentand/oras-
sent. Type 1 diabetes was diagnosed by
American Diabetes Association criteria
within the past 1 month to 3 years (Trial-
Net)orbytheWorldHealthOrganization
1999 criteria within 4 years (ECPT). Pa-
tients being treated with drugs that inﬂu-
ence -cell function or inﬂuence insulin
sensitivity were excluded.
TrialNet randomly allocated subjects
8–35 years of age to receive either two
MMTTs followed by two GSTs or the op-
posite sequence 3–10 days apart. ECPT
randomly allocated subjects to receive
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or MMTT. Subjects were stratiﬁed by age
(8–17 vs. 18–35 years) and duration of di-
abetes (1 year  3 months, 2 years  6
months, or 4 years  12 months) with ap-
proximately equal numbers within each
stratum. The latter two duration subgroups
were randomly allocated together.
The MMTTs and GSTs were initiated
before10 A.M.Subjectsreceivingacontin-
uous subcutaneous insulin infusion (in-
sulin pump) could continue to use the
usual basal rate. Subjects were instructed
to withhold long-acting insulin on the
morning of the test. TrialNet allowed use
of rapid-acting insulin by injection or
continuous subcutaneous insulin infu-
sion up to 2 h before the test and short-
acting insulin up to 6 h before the test.
ECPT subjects withheld rapid or short-
acting insulin for 6 h before the test. Tests
wererescheduledifthesubjecthadacap-
illary glucose value 200 mg/dl or 70
mg/dl. C-peptide concentrations are pre-
sented as picomoles per milliliter.
Statistical methods
The ECPT GST only obtained a 6-min
value, which was treated as the peak. The
poststimulus area under the curve (AUC)
was calculated using the trapezoidal rule.
The mean AUC (in picomoles per millili-
ter) is the AUC divided by the time of the
test. Distributions were positively
skewed, and a log transformation was
used.
The covariate-adjusted mean C-
peptide value for MMTT and GST was es-
timated, and the difference was tested
using normal error regression models for
repeated measures (4). The reliability of
repeated MMTT or GST tests in the same
subject was assessed by the intraclass cor-
relation coefﬁcient (5). The difference in
reliability of the MMTT versus the GST in
TrialNet was tested (6) using subjects
whocompletedallfourvisits.Allanalyses
wereperformedusingtheStatisticalAnal-
ysis System (SAS Institute, Cary, NC).
RESULTS— TrialNet randomly allo-
cated 77 subjects to receive two MMTTs
followed by two GSTs and 71 subjects to
receive the opposite sequence. Of these,
123 completed all four tests, 15 com-
pletedthreeofthefourtests,and10com-
pleted one or two of the tests. ECPT
randomly allocated 59 subjects to receive
twoGSTsfollowedbyasingleMMTTand
59 subjects to receive the opposite se-
quence. Of these, 115 completed three
tests and 3 completed only one test. The
baseline characteristics were similar
within each sequence group within each
study and were comparable across the
two studies with the exception of differ-
ences by design in duration of type 1 di-
abetes (Table 1). (See also supplemental
Tables A1–A6 and Figs. A1 and A2 in the
online appendix.)
Measurable values
The C-peptide assay cannot measure a
value below the lower limit of quantiﬁca-
tion (LOQ). In TrialNet, the LOQ was
lowered during the study. Among assays
completed with the new limit, C-peptide
was measurable in 88% of the basal sam-
ples, 87–95% of stimulated MMTT sam-
ples, and 92–94% of stimulated GST
samples. Results in the ECPT were simi-
lar. There were no signiﬁcant differences
either between tests (MMTT versus GST)
or between studies (TrialNet versus
ECPT). Specimens with nonmeasurable
C-peptidewereassignedtheLOQvalueat
the time of testing.
C-peptide values
In TrialNet, the MMTT values increased
steadily over the ﬁrst hour and then in-
creased more slowly during the second
hour, nearly doubling over the fasting
concentration. The GST values reached a
peakat6minandthendeclined.Asimilar
pattern was observed in the ECPT among
the 82 subjects in the same range of age
(8–35 years) and duration (3 months–3
years) as in TrialNet. The mean  SE
time to the peak value was 88.4 
2.5 min for the TrialNet MMTT, 80.3 
10.7 min for the ECPT MMTT, and
5.8  0.3 min for the TrialNet GST.
Summary measures from each test were
highly correlated. The correlations be-
tweenMMTTfastingandstimulatedpeak
and between MMTT fasting and AUC
were at least 0.92; those for the GST mea-
sures were slightly lower.
Table 2 presents fasting and stimu-
lated C-peptide values obtained from the
two tests. In each study, the covariate-
adjusted stimulated MMTT value was sig-
Table 1—Baseline characteristics of the TrialNet and ECPT participants
TrialNet ECPT Combined data*
n 148 118 230
Male sex (%) 91 (61) 70 (59) 138 (60)
Age (years)
Median (range) 15 (8–35) 19 (8–40) 16 (8–35)
Means  SD 16.2 (6.19) 20.3 (7.54) 17.2 (6.53)
Categories
8–12 years (%) 51 (34) 26 (22) 73 (32)
13–17 years (%) 49 (33) 26 (22) 66 (29)
18 years (%) 48 (32) 66 (56) 91 (40)
Race
White 128 (86) 116 (98) 208 (90)
African American 6 (4) 0 (0) 6 (3)
American Indian 3 (1) 0 (0) 3 (1)
Asian 4 (3) 1 (0.85) 5 (2)
Other 7 (5) 1 (0.85) 8 (3)
Ethnicity
% Hispanic 10 (7) N/A N/A
Duration of type 1 diabetes
(years)
Median (range) 1.36 (0.08 – 2.98) 2.32 (0.75–4.97) 1.49 (0.08 – 2.98)
Mean  SD 1.4  0.88 2.5  1.27 1.54  0.84
Categories
0t o1 year 60 (41) 15 (13) 75 (33)
1t o2 years 39 (26) 34 (29) 72 (31)
2t o3 years 49 (33) 34 (29) 83 (36)
3t o4 years N/A 14 (12) N/A
4t o5 years N/A 21 (18) N/A
A1C (%) 7.3  1.4
Data are n (%), median (range), and means  SD. *Restricted to TrialNet and ECPT study subjects with
diabetes duration of 3 months to 3 years and 8–35 years of age. N/A, not applicable.
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MMTT-stimulated values in TrialNet
tended to be higher than those from the
ECPT. However, in a further analysis
(data not shown) using the subset of
ECPT subjects in the same range of age
and duration of diabetes as in the Trial-
Net, the MMTT stimulated values were
equivalent in the TrialNet and ECPT, al-
though the TrialNet basal value remained
signiﬁcantlyhigherthanthatintheECPT.
Covariate effects on C-peptide
Peak stimulated MMTT and GST values
were positively associated with fasting C-
peptide. Fasting glucose was inversely as-
sociated with peak MMTT but not peak
GST values. Age and duration of diabetes
wereassociatedwithpeakC-peptideonly
in the TrialNet studies. Similar associa-
tions were observed after exclusion of the
small numbers of subjects with a fasting
glucose measurement outside of 70–200
mg/dl on the day of the test.
In the TrialNet but not in the ECPT,
there was a signiﬁcant interaction be-
tween age and test type (MMTT versus
GST) for both the peak and the AUC
meanvalues(P0.01foreach),adjusted
for other covariates. Figure 1 shows that
the mean peak values with MMTT tended
to increase with increasing age, especially
among those with duration of diabetes of
1 year (Fig. 1A), whereas those with
GST decrease with increasing age. Thus,
the difference between the MMTT and
GST peak values also increased with age.
Reproducibility and reliability
Figure 2 shows the relationship between
peakandAUCvaluesfromtherepeattests
for each subject. For each test, the rela-
tionship is strongly linear, with a high R
2.
The correlation coefﬁcients (reliability)
betweentheduplicatevalueswerehighin
both studies, although those among the
duplicatefastingvalueswerelower(about
r  0.90) than those among the stimu-
lated values. Further, the correlations
amongstimulatedMMTTvaluesweresig-
niﬁcantly higher than those among the
GST values. The correlations were similar
intheTrialNetandECPTandamongsub-
group categories of sex, age, and duration
of diabetes.
Adverse effects
The incidence of adverse effects was sub-
stantially higher with the GST than with
the MMTT. With the GST, the incidence
of nausea was 95% in 8–12 year olds,
falling to 66% in those aged 18 years.
Preference
In TrialNet, 53% of subjects preferred the
MMTT to the GST. The preference de-
pended on age: 86% of those aged 13
years preferred the MMTT versus 45% of
those aged 13–17 years and 30% of those
aged 18 years (P  0.01). Male and fe-
male subjects did not differ signiﬁcantly:
61% of female versus 48% of male sub-
jects preferred the MMTT (P  0.17).
Among subjects who preferred the
MMTT, 85% cited nausea experienced
during the GST as a reason. Among those
who preferred the GST, 94% cited the
shorter duration of the test as a reason.
CONCLUSIONS— Retention of -cell
function in type 1 diabetes, as measured
by stimulated C-peptide response, results
in improved glycemic control and re-
duced incidence of hypoglycemia, reti-
nopathy, and nephropathy (3,7). Thus,
intervention studies aimed to preserve
-cell function have usually measured
plasma C-peptide after either a liquid
mixed meal (MMTT) or an intravenous
injection of glucagon (GST). However,
the scientiﬁc validity of the MMTT versus
the GST and the relative tolerability and
practicality have not been deﬁnitively
studied.
Two parallel studies have provided
clear, concordant results. On repeat test-
ing 3–10 days apart, both tests provided
highlyreliable(reproducible)measuresof
stimulated C-peptide responses (more so
withtheMMTT),overawiderangeofage
and diabetes duration. Thus, changes in
these measures over time in clinical trials
(and in individual subjects) can be attrib-
uted to progression of disease and/or inﬂu-
enceoftherapy.Thesedataalsoconﬁrmthe
fact that almost all individuals with type 1
diabetes with a duration of up to 4 years
have measurable stimulated C-peptide,
even with an undetectable fasting value,
and that most maintain clinically mean-
ingful amounts (0.2 pmol/ml) as de-
ﬁned by the Diabetes Control and
Complications Trial (DCCT) (7).
Both studies also show that the
MMTT is a more sensitive test of residual
-cell function, with the peak C-peptide
response being signiﬁcantly greater than
that in the GST. In the MMTT, the peak
response occurred at about 90 min com-
pared with 6 min for the GST, thus con-
ﬁrming the selection of this time point for
the GST in the ECPT. In multivariate
models, longer diabetes duration and
younger age were associated with a
lower C-peptide response to the MMTT
in the TrialNet but not the ECPT, per-
haps owing to the smaller number of
testsand/orthelongerallowedduration
of diabetes. Further, the difference in
peak response with MMTT versus GST
increased with age.
Use of a ﬁxed glucagon dose, rather
thandosingbasedonweight,aswasdone
withthemixedmeal,mayhaveresultedin
lower peak C-peptide responses in the
GST. However, this is unlikely because
identical results are obtained after adjust-
ment for weight; the greater sensitivity of
Table 2—Fasting and stimulated C-peptide concentrations
TrialNet ECPT
MMTT GST MMTT GST
n 143 135 116 117
Tests 278 271 174 174
Fasting (pmol/ml) 0.17 (0.14–0.19) 0.17 (0.15–0.20) 0.07 (0.05–0.08) 0.07 (0.05–0.08)
Peak stimulated (pmol/ml) 0.40 (0.38–0.42) 0.30 (0.28–0.32)* 0.13 (0.12–0.15) N/A
90-min MMTT/6-min GST (pmol/ml) 0.36 (0.34–0.38) 0.27 (0.25–0.28)* 0.12 (0.11–0.13) 0.10 (0.09–0.10)*
AUC mean (pmol/ml) 0.31 (0.29–0.33) 0.25 (0.24–0.26)* 0.11 (0.10–0.11) N/A
Data are geometric means (95% CI). Geometric means, calculated as expmean log(x), are from a mixed-model analysis of the log(C-peptide) adjusted for fasting
glucose concentration, age, sex, continuous diabetes duration, test order, and sequence group. Analyses of stimulated values were also adjusted for basal log(C-
peptide). Analyses were conducted separately for TrialNet and EPCT. *P  0.0001 for the comparison between the TrialNet GST and MMTT. N/A, not applicable.
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tin effect in which an oral glucose stimulus
elicits greater insulin secretion because of
the actions of gastric inhibitory polypep-
tide and glucagon-like peptide 1 com-
pared with a similar intravenous
stimulus. Although there is a known im-
pairment in the incretin effect early in
type1diabetes(8),thesedatasuggestthat
this impairment may be inﬂuenced by
age. Alternatively, the insulin response to
glucagon may be inherently less than the
response to the combined stimuli of fat,
protein, and carbohydrate, a hypothesis
that could be tested in individuals with-
out type 1 diabetes.
Because glucose affects the C-
peptide response (9), the MMTT and
GST were performed only if the fasting
blood glucose by meter was within 70–
200 mg/dl. Within this range, however,
the fasting glucose signiﬁcantly affected
the MMTT C-peptide response. Thus,
for intervention trials, the distributions
of fasting glucose values on the day of
the test should be comparable across
groupsorcontrolledforinthestatistical
analysis.
Nausea occurred in 75–81% of the
GSTs and was more prevalent among
younger subjects, perhaps owing to the
ﬁxed glucagon dose regardless of body
weight. The relatively high frequency is
possibly due to directed questioning.
Most episodes of nausea were mild, al-
though 5–11% involved vomiting.
Most subjects preferred the MMTT.
However, older individuals, who were
moreconcernedwithtimeandwhoexpe-
rienced less nausea, preferred the GST.
Nevertheless, compliance with the se-
quence of tests was high; 83% of TrialNet
subjects completed all four tests and 93%
completed three or four tests, and 97% of
ECPT subjects completed all three tests,
all within a 1 month period. Thus, it is
unlikely that the choice of MMTT versus
GST will affect compliance with testing in
a clinical trial.
Recently, C-peptide response during
a two-phase glucose-clamp procedure
was used to measure -cell function (10),
which poses a substantial additional bur-
denonthesubjectandinvestigator.How-
ever,responsestothisprocedurehavenot
been compared with those for the GST or
MMTT in subjects with type 1 diabetes.
An arginine stimulation test (AST) has
also been used, particularly in post-
transplant studies. The AST, like the
GST,isshort,butunliketheGSTitdoes
not cause nausea and thus might be the
test with the lightest subject burden.
One small study did not show any sig-
niﬁcant differences in sensitivity
between the AST and MMTT (11); how-
ever, it did not assess reproducibility or
overall comparability.
Figure 1—TrialNet mean peak C-peptide (solid lines) and 95% CI bands (dotted lines), from an
MMTT(uppersolidlines)andaGST(lowersolidlines)withrespecttotheageofonsetinsubjects
with duration of type 1 diabetes 1 year (A), 1–2 years (B), and 2–3 years (C) obtained from
separate models within each duration category with an interaction between test (MMTT versus
GST) and age at onset of type 1 diabetes, adjusted for fasting C-peptide, fasting glucose, weight,
visit number, and randomization group.
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time consuming and thus may not pro-
vide beneﬁts in clinical practice beyond a
fasting or a random C-peptide measure-
ment. As shown herein, a fasting (basal)
C-peptide value has a high correlation
with the preferred MMTT mean AUC
response (r  0.95 and 0.93 in the two
studies; see supplemental material in
the online appendix) and a random C-
peptide value has been shown to differ-
entiate subjects with type 1 versus type
2 diabetes (12). However, the emphasis
on stimulated C-peptide levels in type 1
diabetes stems from the DCCT demon-
stration that stimulated C-peptide re-
sponse at baseline in the intensive
therapy group was directly associated
with improved glycemic control, with
lower risks of microvascular complica-
tions and less hypoglycemia (1,7). The
DCCT has not published an analysis of
the like associations with the fasting C-
peptide levels. Without a formal study
using a fasting or random C-peptide
value in addition to a stimulated test, it
is not possible to determine which is
more clinically meaningful in an indi-
vidual subject.
In summary, two parallel studies de-
ﬁnitively show that the MMTT is superior
to the GST when performed under stan-
dardized conditions. The MMTT is more
sensitive, providing higher poststimulus
C-peptide responses; is more reproduc-
ible;andisbettertoleratedandthusisthe
preferred method to measure residual
-cell function in clinical trials in type 1
diabetes. Clinicians interpreting results
from clinical trials to arrest the type 1 di-
abetes disease process should be aware
that these two commonly used outcome
measures are not directly comparable.
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